Stable Cannabinoid Formulations via Synthetic Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid pharmaceutical formulations, particularly those containing cannabidiol, are often contaminated with delta-9-tetrahydrocannabinol, a Schedule I drug, making them less accessible and posing undesirable psychoactive side effects, and there is a need for stable, substantially pure cannabidiol formulations for treating various diseases and disorders.
Innovation Solution
Development of stable pharmaceutical formulations comprising 0.1 to 40% cannabidiol and 10 to 95% lipid, with options for being alcohol-free or containing ethanol, and incorporating antioxidants like alpha-tocopherol, designed for oral administration, which are synthetically synthesized to ensure high purity and minimal delta-9-tetrahydrocannabinol content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If commercially available cannabidiol is used, then treatment accessibility is improved, but contamination with delta-9-tetrahydrocannabinol occurs causing psychoactive side effects
Solution Approach 1:
The patent applies extraction by isolating cannabidiol from delta-9-tetrahydrocannabinol through synthetic methodology. The synthesis process selectively produces cannabidiol while excluding the psychoactive contaminant, effectively extracting the desired compound from the problematic mixture that characterizes commercially available products.
Solution Approach 2:
The patent changes the chemical composition parameters by using synthetic production methods that achieve high purity cannabidiol (greater than 98%). This parameter change in purity and composition eliminates the delta-9-tetrahydrocannabinol contamination present in commercially extracted products while maintaining therapeutic efficacy.
2Object-affected harmful factors
If cannabidiol is synthesized to high purity, then psychoactive side effects are reduced, but manufacturing complexity increases
Solution Approach 1:
The patent converts the challenge of synthetic production into a benefit by using controlled chemical synthesis to achieve high purity. What could be seen as a complexity (synthetic methodology) becomes advantageous because it provides precise control over product purity, eliminating contaminants while maintaining ease of production through established chemical processes.
3Stability of the object's composition
If cannabinoid formulations are stabilized using traditional methods, then formulation stability is improved, but contamination with delta-9-tetrahydrocannabinol persists
Solution Approach 1:
The patent extracts cannabidiol from the complex mixture of cannabinoids through selective synthetic production. This extraction approach at the production stage, rather than the formulation stage, achieves both high purity (greater than 98%) and formulation stability by eliminating the source of delta-9-tetrahydrocannabinol contamination.
Solution Approach 2:
The patent uses composite material principles by combining cannabidiol with lipids and other excipients in specific formulations. These composite formulations maintain stability while preserving the high purity of synthetically produced cannabidiol, creating a stable delivery system that does not reintroduce contaminants.
Data Source
AI summary
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.